A 2026 systematic review confirms that even minimal opioid exposure from routine dental procedures carries a measurable risk of persistent use and substance use disorder. Among nearly 800,000 Ontario patients who received initial dental opioid prescriptions, 4.4% developed persistent opioid use — and patients prescribed opioids after low-pain procedures showed the highest relative risk.
As of September 2026, dental opioid prescribing remains one of the most underestimated risk factors in clinical practice. A comprehensive systematic review published in the Journal of Stomatology, Oral and Maxillofacial Surgery has synthesized data from multiple countries — including a landmark Ontario dataset of 786,125 patients — to quantify the relationship between dental opioid exposure and subsequent substance use disorders. The findings challenge the assumption that short-course dental opioid prescriptions are inherently low-risk.
What the Systematic Review Found
The review analyzed studies spanning the United States, Canada, and Australia to build the most complete picture yet of dental opioid prescribing risk. The headline numbers are sobering:
- Ontario, Canada: Of 786,125 residents receiving initial dental opioid prescriptions, 34,880 individuals (4.4%) developed persistent opioid use
- United States (commercial insurance): 2.1% of patients receiving dental opioids developed persistent use, compared to 1.0% among those who did not receive prescriptions
- Australia: 1.7% of opioid-naive patients developed persistent use following dental prescriptions
These percentages may appear small in isolation, but applied across the volume of dental opioid prescriptions written annually, they translate to thousands of patients entering a cycle of dependence that begins with a routine dental visit.
The Counterintuitive Finding: Low-Pain Procedures Carry the Highest Relative Risk
Perhaps the most striking finding is that patients undergoing low-pain dental procedures who received opioids demonstrated the highest relative risk for short-term persistent use. This suggests that unnecessary prescribing — writing an opioid prescription where non-opioid alternatives would suffice — poses a particularly acute danger.
The mechanism is straightforward: a patient who genuinely needs opioid-level analgesia after a complex oral surgery is likely to stop when the pain resolves. A patient prescribed opioids after a routine extraction or restorative procedure may be more susceptible to the reinforcing effects of the medication precisely because the pain stimulus is mild or resolves quickly, while the opioid's euphoric and anxiolytic properties persist.
Pro Tip: Canadian dentists should review their post-operative analgesic protocols at least annually. If your default for simple extractions still includes an opioid prescription, consider whether ibuprofen 400 mg alternated with acetaminophen 500 mg every 3 hours covers the expected pain level — for most single-tooth extractions, it does.
Risk Factors That Should Trigger Caution
The review identified several patient-level factors that significantly increase the risk of adverse outcomes following dental opioid exposure:
- Higher prescribed doses: Patients receiving more than 90 morphine milligram equivalents (MME) daily showed an adjusted odds ratio of 1.20 compared to those receiving 20 MME or less — a 20% increased risk of persistent use
- Public insurance recipients: Medicaid patients in the U.S. showed a 3.2% persistent use risk versus 0.9% for privately insured patients, reflecting the intersection of socioeconomic vulnerability and access barriers
- Younger patients: Adolescents and young adults were disproportionately affected, with tooth extractions accounting for 89% of dental opioid prescriptions in this age group
- Female patients: Higher risk was observed across age groups
- Prior substance use history: A strong predictor of adverse outcomes, though many prescribers lack access to this information at the point of care
- Complex chronic conditions: Patients managing multiple health conditions showed elevated susceptibility
What Works: Opioid-Sparing Interventions
The review also assessed interventions designed to reduce postoperative opioid consumption. Two pharmacologic approaches showed clear efficacy:
- Liposomal bupivacaine: A long-acting local anaesthetic that reduced postoperative opioid use by 59% in one study. Only 26.1% of patients in the liposomal bupivacaine group used any opioids, compared to 53.2% in the control group
- Preemptive intravenous paracetamol: Administered before the procedure, this decreased rescue analgesic requirements from 34.3% to 11.4%
A third approach — short behavioural counselling — also showed measurable benefit. A 10-minute educational intervention at the time of prescribing reduced postoperative opioid consumption, though the review notes that no intervention study had sufficient follow-up to demonstrate prevention of clinical opioid use disorder.
Pro Tip: If your practice regularly performs surgical extractions or implant placements, ask your anaesthesia supplier about liposomal bupivacaine availability. The 59% reduction in opioid use is one of the strongest effect sizes in the dental pain management literature.
The Canadian Context: Why This Matters for Ontario Practices
Canada's opioid crisis remains acute. The Public Health Agency of Canada reports that opioid-related harms continue to be a leading cause of death among younger Canadians, and the Ontario data in this review — drawn from ICES (formerly the Institute for Clinical Evaluative Sciences) — is specific to the province's population.
The Royal College of Dental Surgeons of Ontario (RCDSO) does not mandate a specific opioid prescribing protocol, but it does expect members to practise in accordance with current evidence-based standards. The Ontario Narcotics Safety and Awareness Act requires dentists to check a patient's narcotic history through the Narcotics Monitoring System (NMS) before prescribing opioids — a step that directly addresses one of the review's identified risk factors (prior substance use history).
For practices in the Greater Toronto Area and across Ontario, the practical implication is clear: every dental opioid prescription should be a deliberate clinical decision, not a reflexive one. The default for routine procedures should be non-opioid analgesia, with opioids reserved for cases where the expected pain level genuinely exceeds the capacity of NSAIDs and acetaminophen.
Practical Steps for Canadian Dental Practices
Based on the systematic review's findings, here are five evidence-based actions dental practices in Ontario can implement immediately:
- Audit your prescribing patterns quarterly. Pull your last 90 days of opioid prescriptions and categorise them by procedure type. If more than 10% of simple extraction patients received opioids, your protocol likely needs revision
- Implement a two-step analgesic ladder. Step 1: ibuprofen + acetaminophen combination. Step 2: add codeine or tramadol only if Step 1 is contraindicated or insufficient for the specific procedure. Step 3 (hydromorphone, oxycodone) should be exceptional
- Check the NMS before every opioid prescription. This is already a legal requirement in Ontario, but compliance varies. Build it into your workflow so it is automatic, not an afterthought
- Counsel patients at the point of prescribing. The 10-minute educational intervention in the review is a practical model: explain what the medication is, why the shortest effective course matters, and how to dispose of unused tablets
- Document your rationale. When you do prescribe an opioid, record why non-opioid alternatives were insufficient for that specific patient and procedure. This protects both the patient and your professional standing
Frequently Asked Questions
Q: How common is persistent opioid use after a dental procedure in Canada?
According to Ontario data from the 2026 systematic review, 4.4% of patients who received an initial dental opioid prescription developed persistent opioid use — roughly 1 in 23 patients. The risk is highest among patients who receive opioids after low-pain procedures where non-opioid alternatives would have been sufficient.
Q: What is the best non-opioid pain management protocol after a dental extraction?
Current evidence supports alternating ibuprofen 400 mg and acetaminophen 500 mg every 3 hours as the first-line approach for most dental extractions. This combination has been shown to provide analgesia comparable to opioid-containing regimens for routine procedures. For patients with NSAID contraindications, acetaminophen alone or codeine-containing combinations may be considered.
Q: Are Ontario dentists required to check the Narcotics Monitoring System before prescribing opioids?
Yes. Under Ontario's Narcotics Safety and Awareness Act, prescribers — including dentists — are required to check a patient's prescription history through the Narcotics Monitoring System before issuing a prescription for a monitored drug. This legal requirement directly supports one of the systematic review's key recommendations: identifying patients with prior substance use history before prescribing.
EBIKO Dental will continue monitoring developments in dental pain management guidelines and opioid prescribing standards as they affect Canadian dental practices.